Nibal Saad, MD
Medical Oncology · Crawfordsville, INNPI 1376807453
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,896 of the $2,472 with a category attached, or 76.7%. It is spread thinly across 39 manufacturers, the largest accounting for just 9.4% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for medical oncology clinicians in IN, where the typical reported total is $2,472.
Across 89 payments — averaging $27.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Histosonics, Inc.$233
- Pharmacyclics LLC, An Abbvie Company$222
- Johnson & Johnson$212
- Astellas Pharma US Inc$176
- Seagen Inc.$168
- E.r. Squibb & Sons, L.L.C.$151
- plus $1K from 33 others
Across 18 payments — averaging $20,462 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$327K
- Daiichi Sankyo Inc.$26K
- Janssen Research & Development, LLC$15K
- EMD Serono, Inc.$170
What the payments were for
- Food & beverage$1,89677%
- Education$57723%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Histosonics, Inc. | 1 | $233 |
| Pharmacyclics LLC, An Abbvie Company | 4 | $222 |
| Johnson & Johnson(2 entities) | 10 | $212 |
| Astellas Pharma US Inc | 2 | $176 |
| Seagen Inc. | 3 | $168 |
| E.r. Squibb & Sons, L.L.C. | 6 | $151 |
| Amgen | 6 | $113 |
| Clovis Oncology, Inc. | 2 | $111 |
| Inari Medical, Inc. | 1 | $98 |
| Genentech USA, Inc. | 3 | $90 |
| AstraZeneca(2 entities) | 6 | $87 |
| Pfizer | 4 | $73 |
| Merck | 4 | $64 |
| Gilead(2 entities) | 4 | $63 |
| Sanofi | 3 | $61 |
| Novartis | 3 | $54 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $44 |
| Menarini Silicon Biosystems, Inc. | 1 | $41 |
| Puma Biotechnology, Inc. | 2 | $39 |
| Exelixis Inc. | 2 | $32 |
| Daiichi Sankyo Inc. | 1 | $30 |
| Partner Therapeutics, Inc. | 1 | $26 |
| Dova Pharmaceuticals | 2 | $26 |
| Bristol Myers Squibb | 1 | $21 |
| AVEO Pharmaceuticals, Inc. | 1 | $20 |
| Agios Pharmaceuticals, Inc. | 1 | $20 |
| Eisai Inc. | 1 | $19 |
| Novocure Inc. | 1 | $18 |
| Lilly USA, LLC | 1 | $17 |
| Regeneron Healthcare Solutions, Inc. | 1 | $16 |
| Jazz Pharmaceuticals Inc. | 1 | $15 |
| Geron Corporation | 1 | $15 |
| Morphosys, US Inc. | 1 | $15 |
| Myovant Sciences Inc. | 1 | $15 |
| Dendreon Pharmaceuticals LLC | 1 | $14 |
| Incyte Corporation | 1 | $14 |
| Paratek Pharmaceuticals, Inc. | 1 | $14 |
| Iovance Biotherapeutics, Inc. | 1 | $13 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- IMBRUVICA$125
How this compares
$2,472 in reported general payments places this provider in the 50th percentile of 67 medical oncology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 47 | $780,533 |
| ImbruvicaIbrutinib | 47 | $772,544 |
| BrukinsaZanubrutinib | 37 | $456,627 |
| Lenalidomide | 34 | $423,005 |
| IbrancePalbociclib | 13 | $214,226 |
| CalquenceAcalabrutinib Maleate | 12 | $173,559 |
| InlytaAxitinib | 11 | $160,663 |
| XtandiEnzalutamide | 11 | $159,864 |
| SprycelDasatinib | 13 | $152,366 |
| EliquisApixaban | 146 | $118,811 |
| VenclextaVenetoclax | 11 | $60,737 |
| XareltoRivaroxaban | 49 | $29,756 |
| Abiraterone Acetate | 15 | $26,645 |
| Exemestane | 26 | $7,541 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 121 | $2,799 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $21 | $780,53347 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $222 | $772,54447 claims |
| PfizerIbrance, Inlyta, Eliquis | $73 | $493,699170 claims |
| AstraZenecaCalquence | $87 | $173,55912 claims |
| Astellas Pharma US IncXtandi | $176 | $159,86411 claims |
| E.r. Squibb & Sons, L.L.C.Sprycel | $151 | $152,36613 claims |
| Johnson & JohnsonXarelto | $212 | $29,75649 claims |
| Lilly USA, LLCOlanzapine | $17 | $93768 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 67 medical oncology providers in Indiana.
Other medical oncology in Crawfordsville
- Costantine AlbanyLafayette$212K
- Sunil BabuFort Wayne$166K
- Natraj AmmakkanavarIndianapolis$129K
- Rafat AnsariMishawaka$90K
- Bert OneilIndianapolis$89K
- Pablo BedanoIndianapolis$52K
- Gregory SmithIndianapolis$46K
- Ashwin VasudevamurthyIndianapolis$44K
- Eduardo BraunWestville$39K
- Daniel SonnenburgIndianapolis$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.